THE ASSOCIATION BETWEEN THE USE OF TIRZEPATIDE AND THE INEFFECTIVENESS OF HORMONAL CONTRACEPTIVES
DOI:
https://doi.org/10.63330/aurumpub.036-006Keywords:
Tirzepatide, Hormonal contraceptives, Drug interaction, GLP-1, Contraceptive ineffectivenessAbstract
Tirzepatide, a dual agonist of GIP and GLP-1 receptors, has been widely used in the treatment of type 2 diabetes mellitus and, more recently, in the management of obesity. Despite its metabolic efficacy, relevant clinical concerns arise regarding its interaction with oral hormonal contraceptives, especially concerning the possible reduction in their effectiveness. This article analyzes the pharmacological mechanisms involved, the available clinical evidence, the limitations of existing studies, and the practical implications for women's reproductive health.
Downloads
References
1. SKELLEY, J. W.; SWEARENGIN, K.; YORK, A. L.; GLOVER, L. H.The impact of tirzepatide and glucagon-like peptide-1 receptor agonists on oral hormonal contraception. Journal of the American Pharmacists Association, 2024.Disponível em: https://pubmed.ncbi.nlm.nih.gov/37940101/.A comprehensive review on the pharmacokinetics and drug-drug interactions of approved GLP-1 receptor agonists and the dual GLP-1/GIP receptor agonist tirzepatide. Pharmacology C Therapeutics, 2025.
2. KETTNER, J. et al.Glucagon-like peptide-1 receptor agonists and reproductive health considerations. Current Opinion in Endocrinology, Diabetes and Obesity, 2025.Disponível em: https://pubmed.ncbi.nlm.nih.gov/40906565/.
3. ELI LILLY AND COMPANY. A study of the effect of tirzepatide on the pharmacokinetics of oral contraceptives. ClinicalTrials.gov Identifier: NCT04172987.Disponível em: https://clinicaltrials.gov/study/NCT04172987.
4. MEDICINES AND MEDICAL DEVICES SAFETY AUTHORITY (MEDSAFE). Possible interaction between GLP-1 receptor agonists and oral contraceptives. Wellington, 2025.Disponível em: https://www.medsafe.govt.nz/committees/marc/reports/203-3.2.1-GLP- 1AndOralContraceptives.pdf.
5. THERAPEUTIC GOODS ADMINISTRATION (TGA).Updated contraception advice for Mounjaro (tirzepatide). Canberra, 2024.Disponível em: https://www.tga.gov.au/news/safety-updates/updated-contraception- advice-mounjaro-tirzepatide.
6. DRUGS.COM.Ethinyl estradiol and tirzepatide drug interaction report.Disponível em: https://www.drugs.com/drug-interactions/ethinyl- estradiol-with-tirzepatide-1039-0-4363-0.html.
7. REPRODUCTIVE HEALTH ACCESS PROJECT.Possible drug interaction between GLP-1 agonists and oral contraceptives.Disponível em: https://www.reproductiveaccess.org/resource/possible-drug-interaction- between-glp-1-agonist-and-oral-contraceptives/.
8. SKELLEY, J. W. et al. The impact of tirzepatide and GLP-1 receptor agonists on oral hormonal contraception. Journal of the American Pharmacists Association, 2024.Disponível em: https://www.japha.org/article/S1544- 3191(23)00370-9/pdf.
9. U.S. FOOD AND DRUG ADMINISTRATION (FDA).Mounjaro® (tirzepatide) prescribing information. Silver Spring, 2024.Disponível em: https://www.accessdata.fda.gov.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
